scientific article published on 11 August 2018

AttributesValues
rdf:type
description
  • wetenschappelijk artikel (nl)
  • наукова стаття, опублікована в листопаді 2018 (uk)
  • im August 2018 veröffentlichter wissenschaftlicher Artikel (de)
  • artículu científicu espublizáu n'agostu de 2018 (ast)
  • scientific article published on 11 August 2018 (en)
  • 2018 թվականի օգոստոսի 11-ին հրատարակված գիտական հոդված (hy)
publication date
publication date
language of work or name
language of work or name
exact match
exact match
cites work
cites work
author name string
author name string
  • Emilio Bouza
  • Maria J G T Vehreschild
  • Florian Thalhammer
  • Areti Georgopali
  • Graham Wetherill
  • Joop van Oene
  • Surabhi Taori
rdfs:label
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
skos:prefLabel
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
name
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
author
author
title
title
  • Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
page(s)
page(s)
  • 2097-2106
instance of
instance of
main subject
main subject
PubMed ID
PubMed ID
PubMed ID
  • 30099637
published in
published in
issue
volume
issue
  • 11
volume
  • 37
Faceted Search & Find service v1.16.117 as of May 05 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software